AbbVie (XSWX:ABBV) E10: CHF3.71 (As of Mar. 2026)


XSWX:ABBV AbbVie Inc XSWX:ABBV
65 GF Score
Price CHF206.75
GF Value CHF172.03
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie E10?

AbbVie XSWX:ABBV -0.39% 65 E10 is CHF3.71 as of Mar. 2026. GuruFocus rates XSWX:ABBV with a GF Score™ of 65/100 and a GF Value™ of CHF172.03 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

AbbVie's adjusted earnings per share data for the three months ended in Mar. 2026 was CHF0.307. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is CHF3.71 for the trailing ten years ended in Mar. 2026.

During the past 12 months, AbbVie's average E10 Growth Rate was -2.10% per year. During the past 3 years, the average E10 Growth Rate was 1.80% per year. During the past 5 years, the average E10 Growth Rate was 6.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of AbbVie was 11.10% per year. The lowest was 1.80% per year. And the median was 6.40% per year.

As of today (2026-07-07), AbbVie's current stock price is CHF206.75. AbbVie's E10 for the quarter that ended in Mar. 2026 was CHF3.71. AbbVie's Shiller PE Ratio of today is 55.73.

During the past 13 years, the highest Shiller PE Ratio of AbbVie was 55.67. The lowest was 24.95. And the median was 35.74.


AbbVie  (XSWX:ABBV) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

AbbVie's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=206.75/3.71
=55.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of AbbVie was 55.67. The lowest was 24.95. And the median was 35.74.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


AbbVie E10 Related Terms


AbbVie E10 Historical Data

* Premium members only.

The historical data trend for AbbVie's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie E10 Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 3.71

XSWX:ABBV vs MRK, JNJ, AMGN: E10 Comparison

For the Drug Manufacturers - General subindustry, AbbVie's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AbbVie's Shiller PE Ratio falls into.


XSWX:ABBV
65GF Score
AbbVie Inc XSWX:ABBV
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AbbVie's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.307/330.2130*330.2130
=0.307

Current CPI (Mar. 2026) = 330.2130.

AbbVie Quarterly Data

per share eps CPI Adj_EPS
201606 0.950 241.018 1.302
201609 0.944 241.428 1.291
201612 0.866 241.432 1.184
201703 1.062 243.801 1.438
201706 1.152 244.955 1.553
201709 0.972 246.819 1.300
201712 0.030 246.524 0.040
201803 1.650 249.554 2.183
201806 1.247 251.989 1.634
201809 1.753 252.439 2.293
201812 -1.225 251.233 -1.610
201903 1.651 254.202 2.145
201906 0.484 256.143 0.624
201909 1.248 256.759 1.605
201912 1.847 256.974 2.373
202003 1.938 258.115 2.479
202006 -0.438 257.797 -0.561
202009 1.180 260.280 1.497
202012 0.009 260.474 0.011
202103 1.850 264.877 2.306
202106 0.381 271.696 0.463
202109 1.643 274.310 1.978
202112 2.081 278.802 2.465
202203 2.333 287.504 2.680
202206 0.495 296.311 0.552
202209 2.151 296.808 2.393
202212 1.286 296.797 1.431
202303 0.120 301.836 0.131
202306 1.026 305.109 1.110
202309 0.900 307.789 0.966
202312 0.398 306.746 0.428
202403 0.684 312.332 0.723
202406 0.688 314.175 0.723
202409 0.746 315.301 0.781
202412 -0.018 315.605 -0.019
202503 0.636 319.799 0.657
202506 0.423 322.561 0.433
202509 0.080 324.800 0.081
202512 0.813 324.054 0.828
202603 0.307 330.213 0.307

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of CHF3.71 mean?
AbbVie (XSWX:ABBV) has a E10 of CHF3.71 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on AbbVie and its competitors.
Is AbbVie's E10 too high?
AbbVie's current E10 is CHF3.71. Overall, AbbVie has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's E10 compare to MRK and JNJ?
AbbVie's E10 of CHF3.71 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on AbbVie and its competitors. AbbVie's current E10 is CHF3.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (XSWX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF172.03, compared to a current price of CHF206.75 — trading 20.2% above its estimated fair value. The current E10 is CHF3.71. AbbVie's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For AbbVie (XSWX:ABBV), the current E10 is CHF3.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (XSWX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of CHF206.75 is trading 20.2% above its estimated GF Value™ of CHF172.03. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for XSWX:ABBV:

  • E10: CHF3.71
  • GF Value™: CHF172.03 vs. price of CHF206.75 (20.2% above fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the XSWX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
65GF Score

Get the complete analysis for XSWX:ABBV

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF206.75
Price
CHF172.03
GF Value